Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

1672050

registered interest
date	21/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the impact to the NHS of the 16.9 per cent uptake rate, as at 29 October, for the autumn COVID-19 booster vaccine by immunocompromised patients; and what steps they will take to increase uptake among that cohort before the vaccination programme is due to end on 15 December.
tabling member printed	Lord Mendelsohn
uin	HL477
answer	answer is ministerial correction date of answer 21/12/2023 answer text <p>Data published by NHS England reported the number of immunosuppressed individuals aged between five and 64 years old that had received vaccination by 29 October 2023 as 326,143. It is not understood where the 16.9% uptake rate within the question has been derived. The published data shows a total number of individuals who have received autumn vaccination broken down by four cohorts.</p><p>We continue to work with NHS England and the UK Health Security Agency to improve immunosuppressed uptake nationally, by understanding drivers of hesitancy, improving the quality of our published data, ensuring it is easy and convenient to book and access vaccinations, and by continuing a variety of campaign activities throughout the winter including the Get Winter Strong campaign. This was launched on 1 November 2023 and encourages those eligible, specifically the clinically most vulnerable, who have not yet come forward for the flu and COVID-19 vaccines to do so.</p><p>NHS England has produced and shared a range of targeted communications materials encouraging people who are immunosuppressed to take up their offer of a COVID-19 booster vaccine, including posters, display screen visuals and social media cards. There are also materials to raise awareness that immunosuppressed household contacts are also eligible for vaccination. These assets have been translated into 28 languages to reach people from a wide range of communities through their native languages and have helped general practices, vaccination centres, pharmacies and other sites to promote COVID-19 and flu vaccination this autumn and winter.</p><p>The Government’s Chief Medical Officer, Prof Sir Chris Whitty, also wrote to the main charities representing the clinically most vulnerable patient cohorts, to publicise this Autumn’s campaign, and to enable them to signpost the offer to their patient communities.</p><p> </p> answering member printed Lord Markham question first answered 21/12/2023 15:28:27 answering member 4948 label Biography information for Lord Markham
tabling member	4286 label Biography information for Lord Mendelsohn

1624547

registered interest
date	27/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government why they have withdrawn the opportunity for COVID-19 vaccine boosters to people living with the immunocompromised people at risk of severe infection or death from COVID-19.
tabling member printed	Lord Mendelsohn
uin	HL7530
answer	answer is ministerial correction date of answer 10/05/2023 answer text <p>Following advice from the independent Joint Committee on Vaccination and Immunisation (JCVI), in autumn 2022 an extra booster dose was offered to individuals aged 50 years old and over, residents in care homes for older people, frontline health and social care workers, those aged five to 49 years old in a clinical risk group and individuals aged five to 49 years old who were household contacts of people with immunosuppression or carers, as defined in the UK Health Security Agency green book. The autumn programme closed on 12 February 2023 in England.</p><p> </p><p>On 7 March 2023, the Government accepted the advice of the JCVI to offer an additional booster vaccine dose in spring 2023. The primary aim of the COVID-19 vaccination programme continues to be the prevention of severe disease, hospitalisation and mortality, arising from COVID-19. Therefore, the spring booster has been offered to those at highest risk of severe COVID-19, adults aged 75 years old and over, residents in a care home for older adults and individuals aged five years old and over who are immunosuppressed.</p><p> </p><p>The spring booster programme in 2022 also focused on those at highest risk of severe COVID-19 and offered an additional dose to these same targeted groups from 12 years old and up.</p> answering member printed Lord Markham question first answered 10/05/2023 16:33:44 answering member 4948 label Biography information for Lord Markham
tabling member	4286 label Biography information for Lord Mendelsohn

1608434

registered interest
date	28/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what (1) evidential basis, and (2) rationale, the Joint Committee on Vaccination and Immunisation used to determine that family members of, and carers for, people in the clinical risk groups identified in the Green Book are not recommended to receive COVID-19 booster vaccinations.
tabling member printed	Lord Mendelsohn
uin	HL6940
answer	answer is ministerial correction date of answer 12/04/2023 answer text <p>In November 2022, the Joint Committee on Vaccination and Immunisation (JCVI) provided interim advice which indicated that in autumn 2023, persons at higher risk of severe COVID-19 could be offered a booster vaccine dose in preparation for winter 2023 to 2024. As it was interim advice, the JCVI report does not contain any evidential basis for proposed cohorts. Final advice on who will be advised to receive COVID-19 boosters in autumn 2023 will be provided in due course. The considerations for any future decisions will be referenced in JCVI reports and meeting minutes.</p><p> </p><p>In February 2023, JCVI provided advice for the spring 2023 COVID-19 vaccination programme. As a precautionary measure, JCVI advised a spring booster dose for the most vulnerable in the population, as a proportionate response: those over the age of 75 years, residents in a care home for older adults, and those over five years of age who are immunosuppressed. These groups were chosen as they continue to be at highest risk of severe COVID-19.</p><p> </p> answering member printed Lord Markham question first answered 12/04/2023 13:31:48 answering member 4948 label Biography information for Lord Markham
tabling member	4286 label Biography information for Lord Mendelsohn

1608437

registered interest
date	28/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the statement by the Joint Committee on Vaccination and Immunisation COVID-19 vaccination programme for 2023: JCVI interim advice, 8 November 2022, what estimate they have made of the number of vaccinations required to prevent a COVID-19 hospital admission for individuals in clinical risk groups, as outlined in the Green Book; and whether they will provide a link to Appendix A of this statement.
tabling member printed	Lord Mendelsohn
uin	HL6943
answer	answer is ministerial correction date of answer 24/04/2023 answer text <p>The numbers needed to vaccinate (NNV) for the prevention of hospitalisation was calculated to consider the benefits of continued offers of primary vaccination, booster vaccination, the autumn booster and potential boosting in the spring of 2023, for example, for those newly entering a risk group. This calculation estimates the number of people in a particular group who would need to be vaccinated in order to prevent one hospitalisation. The lower the number, the more beneficial vaccination of that group would be.</p><p> </p><p>Strong age effects were seen, as well as large differences within adult ages, by clinical risk group. The oldest age groups and the older individuals in clinical risk groups had the lowest NNV for prevention of hospitalisation. There is also a trend for higher NNV for prevention of hospitalisation when moving from the primary to each booster dose.</p><p> </p><p>The spring 2023 booster is for immunosuppressed people at risk rather than all individuals in a clinical risk group.</p><p> </p><p>The results of NNV by age and clinical risk group are shown in Tables 3b and 4a of Appendix 1, which is attached.</p><p> </p><p>These cover all individuals in a risk group based on analysis of data including the national immunisation register. The NNV has not been broken down into separate clinical risk groups, as outlined in the Green Book.</p> answering member printed Lord Markham question first answered 24/04/2023 14:45:48 answering member 4948 label Biography information for Lord Markham attachment 1 file name Appendix 1_ estimation of number needed to vaccinate to prevent a COVID-19 hospitalisation.pdf title Appendix 1: NNV to prevent hospitalisation
tabling member	4286 label Biography information for Lord Mendelsohn

1608438

registered interest
date	28/03/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what are their reasons for implementing restrictions on the spring 2023 COVID-19 booster programme; and what factors were considered in determining the eligibility criteria for the booster programme.
tabling member printed	Lord Mendelsohn
uin	HL6944
answer	answer is ministerial correction date of answer 12/04/2023 answer text <p>As with all vaccination programmes in the United Kingdom, the decision on which groups are eligible for a particular vaccination programme is only made following careful consideration of the groups most at risk of illness, severe illness, or death because of infection. For COVID-19, the primary aim of the vaccination programme continues to be the prevention of severe disease, both in hospitalisation and mortality, arising from COVID-19.</p><p> </p><p>Therefore, in February 2023, the Joint Committee on Vaccination and Immunisation (JCVI) provided advice for the spring 2023 COVID-19 vaccination programme. As a precautionary measure, JCVI advised a spring booster dose for the most vulnerable in the population, as a proportionate response: those over the age of 75 years, residents in a care home for older adults, and those over five years of age who are immunosuppressed.</p> answering member printed Lord Markham question first answered 12/04/2023 13:33:00 answering member 4948 label Biography information for Lord Markham
tabling member	4286 label Biography information for Lord Mendelsohn

1542103

registered interest
date	14/11/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the position that coronavirus vaccines and immunizations, including prophylactic antibodies, should be assessed through the JCVI.
tabling member printed	Lord Mendelsohn
uin	HL3367
answer	answer is ministerial correction date of answer 28/11/2022 answer text <p>No such assessment has been made. The Joint Committee on Vaccination and Immunisation (JCVI) is an independent expert advisory committee which advises United Kingdom health departments on immunisation. The JCVI’s remit is focused on vaccination rather than antibody treatments and prophylaxis.</p><p> </p><p>The multi-agency RAPID C-19 was established in 2020 to ensure that treatments for COVID-19 are made available safely to National Health Service patients as soon as possible. RAPID C-19 has the relevant expertise in the therapeutic options available and consults experts in an NHS expert working group and the Prophylaxis Oversight Group. The Chief Medical Officer for England has agreed that Evusheld should be referred to the National Institute for Health and Care Excellence for further evaluation, which is underway</p> answering member printed Lord Markham question first answered 28/11/2022 12:45:59 answering member 4948 label Biography information for Lord Markham
tabling member	4286 label Biography information for Lord Mendelsohn

1420008

registered interest
date	04/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many clinically extremely vulnerable people have received their fourth dose of the COVID-19 vaccine.
tabling member printed	Lord Mendelsohn
uin	HL6003
answer	answer is ministerial correction date of answer 11/02/2022 answer text <p>The data regarding fourth doses of COVID-19 vaccines is not yet available in the format requested as it is currently being collated and centrally validated.</p><p> </p> answering member printed Lord Kamall question first answered 11/02/2022 12:37:50 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1420009

registered interest
date	04/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many (1) immunocompromised, or (2) immunosuppressed, people have received their fourth dose of the COVID-19 vaccine.
tabling member printed	Lord Mendelsohn
uin	HL6004
answer	answer is ministerial correction date of answer 11/02/2022 answer text <p>The data regarding fourth doses of COVID-19 vaccines is not yet available in the format requested as it is currently being collated and centrally validated.</p> answering member printed Lord Kamall question first answered 11/02/2022 12:40:10 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1383184

registered interest
date	29/11/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have to monitor (1) immunocompromised patients' antibody levels, and (2) their variation over time, in response to the rollout of the third primary dose vaccination.
tabling member printed	Lord Mendelsohn
uin	HL4489
answer	answer is ministerial correction date of answer 16/12/2021 answer text <p>The UK Health Security Agency (UKHSA) is monitoring the effectiveness of COVID-19 vaccinations in clinical risk groups, including those with immunosuppression. The VirusWatch study monitors antibody response over time following COVID-19 vaccination, including the third primary dose, among individuals with immunosuppression.</p><p>As part of the COVID-19 Immunity National Core Study, the UK Research and Innovation OCTAVE study is examining the immune response to COVID-19 vaccines in clinically at-risk groups. This includes vaccine responses in patients with certain immunosuppressed conditions. These analyses will monitor the duration of immunity from COVID-19 vaccination.</p> answering member printed Lord Kamall question first answered 16/12/2021 15:24:26 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn

1379169

registered interest
date	16/11/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have, if any, to test people with immunodeficiencies for their individual responses to COVID-19 vaccinations.
tabling member printed	Lord Mendelsohn
uin	HL4097
answer	answer is ministerial correction date of answer 01/12/2021 answer text <p>The UK Health Security Agency is working with a range of partners, such as the University College of London, to monitor the effectiveness of COVID-19 vaccinations in clinical risk groups, including those with immunosuppression. The VirusWatch study is underway to monitor antibody response following vaccination among individuals with immunosuppression.</p><p>As part of the COVID-19 Immunity National Core Study, the UK Research and Innovation OCTAVE study is examining the effectiveness of vaccines in clinically at-risk groups. This includes vaccine responses in patients with certain immunosuppressed conditions.</p> answering member printed Lord Kamall question first answered 01/12/2021 11:43:02 answering member 4909 label Biography information for Lord Kamall
tabling member	4286 label Biography information for Lord Mendelsohn